Profound remission in Crohn’s disease requiring no further treatment for 3–23 years: a case series

Table 1 Characteristics of patients achieving prolonged treatment-free remission and endoscopic healing following treatment (N = 10)

Patient	Age, years	Sex	Prior therapies	AMAT (Y/N)	AMAT Regimen	Duration of AMAT (years)	Adjunct therapy	Duration of treatment-free remission (years)
1	47	M	Azathioprine^a	N	–	–	FMT methotrexate vitamin D	4
2	21	M	Prednisone, right hemi-colectomy	Y	Rifabutin; clofazimine; clarithromycin, Ciprofloxacin, metronidazole	1	Anti-TNF infliximab infusion, vitamin D	9
3	56	F	Sulfasalazine; mesalazine^a; azathioprine^a; esomeprazole; Metronidazole^a; Vancomycin^a.	N	–	–	FMT	6
4	43	M	Azathioprine^a; Mesalazine^a; Esomeprazole.	N	–	–	FMT	23
5	17	F	Ciprofloxacin^a, metronidazole^a, azathioprine^a; Prednisone	Y	Rifabutin; clofazimine; clarithromycin, ciprofloxacin, metronidazole and ethambutol	9	Infliximab	18
6	48	F	Mesalazine^a	Y	Rifabutin; clofazimine; clarithromycin, ethambutol	3	FMT	14
7	36	F	Adalimumab; Infliximab (alone); azathioprine^a; ciprofloxacin^a; metronidazole^a	Y	Rifabutin; clofazimine; clarithromycin; metronidazole	2	FMT	3
8	38	F	Mesalazine^a	Y	Rifabutin; clofazimine; clarithromycin, metronidazole, ciprofloxacin	8	Infliximab	8
9	32	F	Prednisone; metronidazole^a; ciprofloxacin^a	Y	Rifabutin; clofazimine; clarithromycin, metronidazole, ciprofloxacin	3	–	8
10	16	F	Mesalazine^a; azathioprine^a	Y	Rifabutin; clofazimine; clarithromycin, ethambutol	8	Infliximab	11

AMAT anti-mycobacterial antibiotic therapy, FMT faecal microbiota transplantation
^aTherapies known to have potential anti-MAP properties

ISSN: 1757-4749